Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NYXH
stocks logo

NYXH

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
3.47M
+174.56%
-0.538
+16.11%
4.61M
+333.16%
-0.535
-10.49%
6.44M
+380.96%
-0.546
-0.82%
Estimates Revision
The market is revising Downward the revenue expectations for Nyxoah SA (NYXH) for FY2025, with the revenue forecasts being adjusted by -5.03% over the past three months. During the same period, the stock price has changed by -18.89%.
Revenue Estimates for FY2025
Revise Downward
down Image
-5.03%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+4.83%
In Past 3 Month
Stock Price
Go Down
down Image
-18.89%
In Past 3 Month
Wall Street analysts forecast NYXH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NYXH is 11.54 USD with a low forecast of 9.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast NYXH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NYXH is 11.54 USD with a low forecast of 9.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 4.810
sliders
Low
9.00
Averages
11.54
High
13.00
Current: 4.810
sliders
Low
9.00
Averages
11.54
High
13.00
Piper Sandler
Overweight
downgrade
$12 -> $9
2025-11-14
Reason
Piper Sandler
Price Target
$12 -> $9
2025-11-14
downgrade
Overweight
Reason
Piper Sandler lowered the firm's price target on Nyxoah to $9 from $12 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 revenue of EUR 2.0M, which came in-line with its estimate and the Street's bogey. The U.S. Genio launch appears to be progressing nicely, with Nyxoah announcing that it has done 15 U.S. implants and received 35 VAC approvals through the end of October. Piper understands the process to receive VAC and prior authorization approvals can be onerous and believes that the Q4 guidance of EUR 3.4M - EUR 3.6M feels appropriately calibrated.
Stifel
Jonathan Block
Strong Buy
Maintains
$15 → $14
2025-04-21
Reason
Stifel
Jonathan Block
Price Target
$15 → $14
2025-04-21
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$15
2025-04-08
Reason
HC Wainwright & Co.
Edward White
Price Target
$15
2025-04-08
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Maintains
$17 → $15
2025-03-26
Reason
HC Wainwright & Co.
Edward White
Price Target
$17 → $15
2025-03-26
Maintains
Strong Buy
Reason
Stifel
Jonathan Block
Strong Buy
Maintains
$16 → $15
2025-03-14
Reason
Stifel
Jonathan Block
Price Target
$16 → $15
2025-03-14
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Edward White
Strong Buy
Reiterates
$17
2024-12-13
Reason
HC Wainwright & Co.
Edward White
Price Target
$17
2024-12-13
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Nyxoah SA (NYXH.O) is -1.94, compared to its 5-year average forward P/E of -6.42. For a more detailed relative valuation and DCF analysis to assess Nyxoah SA 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.42
Current PE
-1.94
Overvalued PE
-0.79
Undervalued PE
-12.05

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-5.51
Current EV/EBITDA
-1.32
Overvalued EV/EBITDA
-0.37
Undervalued EV/EBITDA
-10.64

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
49.37
Current PS
6.32
Overvalued PS
110.29
Undervalued PS
-11.56
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

NYXH News & Events

Events Timeline

(ET)
2025-11-26
05:30:47
Nyxoah Secures Higher Medicare Reimbursement for Genio
select
2025-11-13 (ET)
2025-11-13
17:10:15
Nyxoah Announces Q3 Earnings Per Share of EUR 0.63, Up from EUR 0.50 Last Year
select
2025-09-15 (ET)
2025-09-15
16:12:45
Nyxoah Initiates Patent Infringement Lawsuit Against Inspire Medical
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
12-03NASDAQ.COM
Biotech Stocks Rise After Hours: Clene Jumps Ahead of ALS Update; Werewolf, Biomea, and Dyne Also Gain

  • Clene Inc. Gains: Clene Inc. shares rose 8.53% in after-hours trading after announcing an upcoming investor call regarding its CNM-Au8 program for ALS, despite a regular session decline.

  • Werewolf Therapeutics Update: Werewolf Therapeutics saw a 6.12% increase after hours, likely influenced by investor reactions to its recent presentation at a cancer immunotherapy conference, despite no new news.

  • Biomea Fusion Presentation: Biomea Fusion's stock climbed 7.31% after hours following its announcement of an upcoming presentation on icovamenib data at a major diabetes and cardiovascular disease congress.

  • General Market Trends: Other biotech companies like Denali Therapeutics, TScan Therapeutics, and Nyxoah also experienced after-hours gains, reflecting ongoing investor interest and positioning ahead of regulatory milestones and presentations.

[object Object]
Preview
7.0
12-03Newsfilter
Nyxoah SA Shareholder Robert Taub Exceeds 10% Ownership Threshold
  • Shareholding Change: As of December 1, 2025, Robert Taub and his controlled entity BMI Estate hold 4,360,800 voting rights, representing 10.14% of the total voting rights, indicating a growing influence within Nyxoah SA.
  • Transparency Notification: On December 2, 2025, Taub submitted a transparency notification to Nyxoah, indicating that his shareholding has crossed the 10% threshold, which may impact the company's governance structure.
  • Shareholder Structure: Taub's holdings are managed through BMI Estate and Robelga SRL, the latter being wholly owned by BMI Estate, illustrating the family's control over the company.
  • Future Implications: With Taub's increasing stake, Nyxoah SA may face greater shareholder pressure, potentially enhancing transparency and accountability in strategic decision-making and business development.
[object Object]
Preview
1.0
11-28Newsfilter
Nyxoah to Showcase Innovative OSA Treatment at Piper Sandler Healthcare Conference
  • Management Participation: Nyxoah will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, showcasing its innovative treatment solutions for Obstructive Sleep Apnea (OSA), which is expected to attract investor interest and enhance the company's visibility.
  • Technological Innovation: The Genio system developed by Nyxoah is a leadless, battery-free neurostimulation therapy aimed at improving the quality of life for OSA patients, aligning with the company's vision to provide better treatment options for patients.
  • Market Recognition: Since receiving the European CE Mark in 2019, the Genio system has successfully completed multiple clinical studies, including the BETTER SLEEP study, which expanded its therapeutic indications and demonstrated its competitive advantages in the market.
  • Regulatory Approval: The company received FDA approval in 2025 for the use of the Genio system in moderate to severe OSA patients, marking a significant expansion into the U.S. market and is expected to drive sales growth.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Nyxoah SA (NYXH) stock price today?

The current price of NYXH is 4.81 USD — it has increased 2.89 % in the last trading day.

arrow icon

What is Nyxoah SA (NYXH)'s business?

Nyxoah SA is a Belgium-based company that produces medical equipment. The company focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.

arrow icon

What is the price predicton of NYXH Stock?

Wall Street analysts forecast NYXH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NYXH is 11.54 USD with a low forecast of 9.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Nyxoah SA (NYXH)'s revenue for the last quarter?

Nyxoah SA revenue for the last quarter amounts to 1.97M USD, increased 55.77 % YoY.

arrow icon

What is Nyxoah SA (NYXH)'s earnings per share (EPS) for the last quarter?

Nyxoah SA. EPS for the last quarter amounts to -0.63 USD, increased 26.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Nyxoah SA (NYXH)'s fundamentals?

The market is revising Downward the revenue expectations for Nyxoah SA (NYXH) for FY2025, with the revenue forecasts being adjusted by -5.03% over the past three months. During the same period, the stock price has changed by -18.89%.
arrow icon

How many employees does Nyxoah SA (NYXH). have?

Nyxoah SA (NYXH) has 147 emplpoyees as of December 05 2025.

arrow icon

What is Nyxoah SA (NYXH) market cap?

Today NYXH has the market capitalization of 206.53M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free